TRANSDERMAL DELIVERY OF OLIGOSACCHARIDES
The present invention relates to a system for facilitating transdermal delivery of oligosaccharides, The system includes an apparatus that generates micro-channels in the skin of a subject and a skin patch. The patch includes a pharmaceutical composition containing an active agent of an oligosaccharide. Particularly, the oligosaccharide has 5 to 20 monosaccharide units, such as a pentasaccharide, which exerts anticoagulant activity. The system is capable of delivering the oligosaccharides into the blood circulation for treating thromboembolic diseases.
1 .- 30 . (canceled)
31 . A method for treating a subject suffering from a thromboembolic disease, the method comprises:
generating a plurality of micro-channels in an area on the skin of the subject; and
affixing a skin patch to the area of the skin in which the plurality of micro-channels is present, the skin patch comprises a therapeutically effective amount of a pharmaceutical composition comprising as an active agent an oligosaccharide of 5 to 20 monosaccharide units, the oligosaccharide having anti-coagulant activity comprising, in anionic form, at least the general formula:
wherein:
R 1 and R 12 each is independently OH, (C 1 -C 4 ) alkoxy, or an oligosaccharide consisting of 1 to 8 monosaccharide units,
R 2 , R 4 , R 5 , and R 8 each is independently OH, (C 1 -C 4 ) alkoxy, or OSO 3 − ,
R 3 , R 7 , and R 11 each is independently NHSO 3 − , (C 1 -C 4 ) alkoxy, OH, or OSO 3 ,
R 6 and R 9 each is independently OSO 3 − , or (C 1 -C 4 ) alkoxy, and
R 10 is OH, (C 1 -C 4 ) alkoxy, OSO 3 − , or COO − ; or a pharmaceutically acceptable salt thereof, further comprising a pharmaceutically acceptable carrier so that the oligosaccharide can be delivered into the blood circulation.
32 . The method according to claim 31 , wherein the oligosaccharide is fondaparinux or a pharmaceutically acceptable salt thereof.
33 . The method according to claim 32 , wherein the oligosaccharide is fondaparinux sodium.
34 . The method according to claim 31 , wherein the oligosaccharide is idraparinux or a pharmaceutically acceptable salt thereof.
35 . The method according to claim 31 , wherein the pharmaceutical composition is formulated as a viscous liquid, liquid, or in a dry form.
36 . The method according to claim 35 , wherein the pharmaceutical composition formulated as a viscous liquid further comprising a water-soluble thickening agent.
37 . The method according to claim 36 , wherein the water-soluble thickening agent is a water-soluble cellulose compound.
38 . The method according to claim 37 , wherein the water-soluble cellulose compound is present in the composition in an amount ranging from about 0.5% (w/w) to about 3.5% (w/w) of the composition.
39 . The method according to claim 35 , wherein the viscous liquid has a viscosity of about 300 cps to about 40000 cps.
40 . The method according to claim 35 , wherein the viscous liquid has a viscosity of about 300 cps to about 3000 cps.
41 . The method according to claim 35 , wherein the pharmaceutical composition formulated as a viscous liquid comprising fondaparinux sodium, hydroxyethyl cellulose, and water, and wherein the composition having a viscosity of about 300 cps to about 3000 cps.
42 . The method according to claim 31 , wherein the patch further comprises at least one of a backing layer, an adhesive, a rate-controlling layer, or a release liner.
43 . The method according to claim 31 , wherein generating the plurality of micro-channels is performed by an apparatus which comprises:
an electrode cartridge comprising a plurality of electrodes; and
a main unit comprising a control unit, which is adapted to apply electrical energy of radio frequency to the electrodes when the electrodes are in vicinity of or in contact with the stratum corneum of the skin, enabling ablation of the stratum corneum in an area beneath the electrodes, thereby generating said plurality of micro-channels.
44 . The method according to claim 31 , wherein the thromboembolic disease is selected from the group consisting of venous thromboembolic diseases and arterial thromboembolic diseases.
45 . The method according to claim 31 , wherein the thromboembolic disease is selected from the group consisting of deep vein thrombosis, pulmonary embolism, thrombophlebitis, arterial occlusion from thrombosis or embolism, arterial reocclusion during or after angioplasty or thrombolysis, restenosis following arterial injury or invasive cardiological procedures, postoperative venous thrombosis or embolism, acute or chronic atherosclerosis, stroke, and myocardial infarction.